Raised LDL cholesterol is a risk factor for cardiovascular disease. We will review the five ways of lowering LDL cholesterol.

There is incontrovertible evidence that LDL cholesterol is a major risk factor in the development of atherosclerotic cardiovascular disease, which remains one of the world’s great killers. There are now five different ways of lowering LDL cholesterol. As well as statins, we now have ezetimibe, bempedoic acid, PCSK9i monoclonal, antibodies, and now inclisiran. We will review their usage in both primary and secondary prevention with particular reference to the new NICE cholesterol guidance which emphasises that treatments should be used in combinations to achieve target LDL values. Identifying at risk patience and optimising levels could substantially reduce the burden of cardiovascular disease in the UK.

This webinar is delivered in partnership with the Primary Care Cardiovascular Society and the Best Practice Show.

Listen to even more top quality clinical content like this at our NEW Best Practice Show in London on 8-9th March 2023, at Olympia London. Please learn more about our next conference and exhibition by clicking here: https://www.bestpracticelondon.co.uk/pccs-webinar

Should you have difficulties viewing the webinar please try the following in order:
• Refresh your web page
• Exit the webinar and re-join
• Try a different browser (Chrome/Firefox)
• Try dialling in to listen with a phone - the UK dial in number is: 01793 250421
  • Cholesterol is in major risk factor for cardiovascular disease
  • Lowering cholesterol substantially reduces cardiovascular events
  • Combinations of lipid lowering therapy is frequently needed
  • There are no five ways of lowering LDL cholesterol approved by NICE
  • The new lipid pathway is a useful tool to help
Dr Derek Connolly (Chair)
Consultant Interventional Cardiologist
Consultant Interventional Cardiologist and Honorary Senior Clinical Lecturer at Birmingham City Hospital, Birmingham UK. Derek trained in Cambridge, London, Edinburgh and San Diego where he was a Carnegie Scholar. Derek has a first class degree in Pharmacology from the University of Edinburgh where he was the Brunton medallist and Keasbey Bursary holder. Derek’s PhD in molecular cardiology is from the University of Cambridge. Derek is the Chief or Primary Investigator of multiple large trials in Cardiovascular medicine. Derek developed one of the UKs first primary angioplasty programmes, and one of the UKs largest cardiac CT programmes.
Helen Williams FFRPS, FRPharmS
Consultant Pharmacist for Cardiovascular Disease, South East London CCG and UCLPartners National Specialty Adviser for CVD Prevention, NHSE and I
Helen is the National Speciality Adviser for CVD Prevention at NHS England and is working on delivery of the national CVD ambitions for AF, Blood Pressure and Cholesterol in the NHS Long Term Plan. Helen has worked as a CVD specialist for more than 25 years across all care settings. She was clinical adviser to the national AF programme and developed the pharmacist-led virtual clinic model to optimise uptake of anticoagulation in AF, which has now been spread nationally. Helen has recently been appointed as one of the long term conditions lead for South East London Integrated Care System and is also working at UCLPartners on the implementation of proactive care frameworks for long-term conditions to support primary care in the post COVID-19 environment.
Register To Watch Recording
First Name*
Last Name*
Email Address*
Job Title*
Address Line 1
Address Line 2
Are you a healthcare professional?*
Marketing Permission
CloserStill Media will use the information you provide on this form to be in touch with you and to provide updates and marketing. We will not share or sell your personal information. You can unsubscribe anytime by clicking the unsubscribe link in the footer of our emails, or by replying to our emails and asking to be unsubscribed. For more information, please read our privacy policy.
Yes, I agree to these terms*
We use BigMarker as our webinar platform. By clicking Register, you acknowledge that the information you provide will be transferred to BigMarker processing in accordance with their Terms of Service and Privacy Policy.